Related Experiment Videos

[CHARM study--new strategy for the treatment of heart failure]

Hiroshi Hasegawa1, Issei Komuro

  • 1Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 20, 2004
PubMed

Insights

Candesartan significantly reduced mortality and hospitalization in heart failure patients, especially those with reduced ejection fraction (LVEF < 40%). This study provides evidence for angiotensin receptor blockers in various heart failure types.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic heart failure (CHF) affects millions globally, necessitating effective treatments.
  • Angiotensin receptor blockers (ARBs) are a key therapeutic class for managing heart failure.
  • The CHARM program is the largest trial series investigating ARBs in CHF.

Purpose of the Study:

  • To evaluate the efficacy of candesartan in diverse chronic heart failure populations.
  • To assess candesartan's impact on mortality and morbidity across different ejection fraction levels.
  • To explore ARB benefits in patients intolerant or already on ACE inhibitors.

Main Methods:

  • Randomized controlled trial design across three distinct patient arms.
  • Arm 1: LVEF < 40%, ACE inhibitor intolerant (n=2028).
  • Arm 2: LVEF < 40%, on ACE inhibitor (n=2548).
  • Arm 3: LVEF > 40% (n=3023).

Main Results:

  • Candesartan demonstrated an overall mortality benefit compared to placebo.
  • Significant reductions in mortality and hospitalization were observed in patients with LVEF < 40%.
  • These findings suggest potential benefits across multiple heart failure phenotypes.

Conclusions:

  • Candesartan offers significant benefits in reducing mortality and hospitalization in heart failure.
  • The drug is effective in patients with reduced ejection fraction, regardless of ACE inhibitor use.
  • This trial provides new evidence supporting ARBs for various types of heart failure.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
239
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
300
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
741